Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data.
Kimyon G, Kalyoncu U, Kiraz S, Bes C, Coşkun N, Yağiz B, Küçükşahin O, Kanitez N, Erden A, Kiliç L, Bilgin E, Kaşifoğlu T, Emmungil H, Koca SS, Akar S, Çinar M, Yazisiz V, Ateş A, Ersözlü D, Gönüllü E, Mercan R, Ertenli İ.
Kimyon G, et al. Among authors: kalyoncu u.
Clin Exp Rheumatol. 2021 Jul-Aug;39(4):852-858. doi: 10.55563/clinexprheumatol/jhpymv. Epub 2020 Sep 4.
Clin Exp Rheumatol. 2021.
PMID: 32896266